SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARRIS - Another partner
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (329)12/29/1997 9:19:00 PM
From: John Metcalf  Read Replies (2) of 353
 
Good question, Miljenko. ARRS/SQNA is already at a very low valuation. The combined market cap of the two companies is $224mm, and they have half of that ($113mm) in cash. There are very few companies selling for twice their cash on hand.

Collaborations of the combined companies account for at least 4 times the technology value of AxyS.

In my view, the valuations are irrationally low right now. There seems to be selling from those who don't like the merger, and also from those who like it but don't expect completion. Not to mention selling to recognize tax losses, and selling related to the general biotech doldrums.

I would not expect buyers to emerge until there is some sense of strategic direction for the new entity.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News